Markets
Jazz Stock Soars 8%, Adding $1.1 Billion, After It Raises 2026 Revenue Forecast
The drugmaker lifted its full-year sales outlook even as a $754 million acquired-research charge pushed the quarter to a loss.
Jazz Pharmaceuticals (JAZZ) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
The drugmaker lifted its full-year sales outlook even as a $754 million acquired-research charge pushed the quarter to a loss.
Earnings
Jazz lifted its 2026 revenue range to $4.775 billion to $4.85 billion while flagging a competitor to its small cell lung cancer drug.
SEC Filings
Jazz booked a $413.4 million operating loss on $1.24 billion of revenue as it also spent $225.0 million on buybacks.
Deals
Record third-quarter revenue of $1,243.0 million met a $483.4 million net loss driven by acquired research expense.
Earnings
The drugmaker estimates a non-deductible research charge from its Actio Biosciences purchase, which closed September 15.
SEC Filings
Jazz plans a formal search for a successor, weighing internal and external candidates, an 8-K shows.